IP Library › Granted Patent US 11,905,510
Granted Patent B2
US 11,905,510 · App. 17/146,849 · Granted Feb 20, 2024

Methods and systems for activating cells to treat aging

Inventors: Todd Frank Ovokaitys (Carlsbad, CA); John Scott Strachan (Edinburgh, GB)
C12N13/00A61K35/28A61K35/51A61K41/00A61K41/0023A61N5/062A61N5/0622A61N5/067A61N2005/0626A61N2005/0659A61N2005/0662
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,905,510
App. No.
17/146,849
Granted
Feb 20, 2024
Kind
B2
Abstract

Harvested stem cells are activated by treating them with an amplitude modulated laser beam having a wavelength lying in the range of 405 to 980 nanometers. The frequency of the laser beam is modulated within a range of 8 to 12 MHz. Using the activated stem cells, tissue can be repaired and regenerated by preparing the unactivated stem cells, treating the unactivated stem cells with an amplitude modulated laser beam having a pre-determined frequency for obtaining activated stem cells, administering the activated stem cells into a body containing the tissue, and using a homing beam to guide the activated stem cells within the body to the location of the tissue.

Claims (19)

1. A method of activating dormant repair cells in a patient, the method comprising:

obtaining dormant repair cells;

activating the dormant repair cells to form activated repair cells by treating the dormant repair cells with an amplitude modulated laser beam having a pre-defined wavelength and a pre-defined amplitude, wherein the activated repair cells have increased telomerase activity relative to the dormant repair cells;

intravenously administering the activated repair cells into the patient; and

transcutaneously applying a homing laser beam along at least one axis such that the laser beam guides the activated repair cells to a location.

2. The method of claim 1 wherein the homing laser beam is generated using a 20% to 90% phase cancellation.

3. The method of claim 1 wherein the dormant repair cells are harvested from at least one of peripheral blood, bone marrow, or fat of the patient.

4. The method of claim 1 , wherein the dormant repair cells are harvested from at least one of cord blood or a placenta of the patient.

5. The method of claim 1 , wherein the dormant repair cells are sourced from a stem cell donor who is genetically matched to the patient.

6. The method of claim 1 wherein the pre-defined wavelength is in a range of 405 to 980 nanometers.

7. The method of claim 1 wherein the amplitude modulated laser beam has a wavelength of 674 nanometers.

8. The method of claim 1 , wherein the amplitude modulated laser beam comprises a string of short duration pulses of sub-femto second duration.

9. The method as claimed in claim 1 wherein, prior to treating the dormant repair cells, the amplitude modulated laser beam is expanded in a range varying between two times to seven times by passing the amplitude modulated laser beam through a beam expander.

10. The method as claimed in claim 1 wherein, prior to treating the dormant repair cells, the amplitude modulated laser beam is passed through a Strachan-Ovokaitys Node Generator.

11. The method as claimed in claim 1 wherein a phase cancellation of the amplitude modulated laser beam is adjusted to achieve a predetermined power output before treating the dormant repair cells.

12. The method as claimed in claim 1 wherein treating the dormant repair cells comprises applying the amplitude modulated laser beam to a container containing the dormant repair cells such that the container is rotated and simultaneously moved up and down in a vertical direction during an activation process.

13. The method as claimed in claim 12 wherein the container is rotated at a speed of one rotation in every 3 to 5 seconds and is moved up and down for a duration of 15 seconds in each direction.

14. The method as claimed in claim 1 wherein, relative to the dormant repair cells, the activated repair cells comprise at least one of an increased expression of an alpha or beta integrin, an increase in CD34, or an enhanced migratory action in a direction of the laser beam.

15. The method of claim 1 further comprising guiding the homing laser beam to direct the activated repair cells toward damaged biological tissue and wherein the damaged biological tissue comprises at least one of myocardial tissue, lung tissue, kidney tissue, blood vessels, immune system cells, bone tissue, teeth, liver tissue, endocrine tissues, pituitary tissue, thymus tissue, intervertebral discs, brain tissue, spinal tissue, pancreatic tissue or nerve tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2021
From: STRACHAN, JOHN SCOTT
To: OVOKAITYS, TODD FRANK
Reel/Frame 054892/0051 →
Continuity (7)
Continuation 16232776 · Dec 26, 2018
Continuation 15349886 · Nov 11, 2016
Continuation In Part 14726457 · May 30, 2015
Provisional Application 62321781 · Apr 13, 2016
Provisional Application 62254220 · Nov 12, 2015
Provisional Application 62006034 · May 30, 2014
Related Publication 20210207121A1 · Jul 8, 2021